SECOND AMENDED AND RESTATED SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • Delaware
This SECOND AMENDED AND RESTATED SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”), is made and entered into as of the first day of July, 2021 (the “Second Restatement Date”), by and between Roman Health Pharmacy LLC, a Delaware limited liability company, having its principal office at 900 Broadway, Suite 706, New York, NY 10003 (“RO”) and Gelesis Inc., a Delaware corporation, having its principal office at 501 Boylston Street, Suite 6102, Boston, MA 02116 (“GELESIS”). RO and GELESIS each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • New York
Pharmaceutical Distribution Agreement (“Agreement”) dated as of Feb 12, 2020 (the “Effective Date”) between Gelesis, Inc., a Delaware Corporation (“Manufacturer”) and Specialty Medical Drugstore, LLC, an Ohio limited liability corporation dba GoGoMeds (“Pharmacy”) and, together with Gelesis, the “[__]” and together with GoGoMeds the “Parties”).
LICENSE, COLLABORATION AND SUPPLY AGREEMENT By and Between GELESIS INC. And CMS Bridging DMCC LICENSE, COLLABORATION AND SUPPLY AGREEMENTLicense, Collaboration and Supply Agreement • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • New York
This License, Collaboration and SUPPLY Agreement (the “Agreement”) is entered into as of June 18, 2020 (the “Effective Date”) by and between Gelesis Inc., a company organized and existing under the laws of the State of Delaware, having its principal offices at 501 Boylston Street, Suite 6102, Boston, MA 02116, USA (“Licensor”) and CMS Bridging DMCC, a company incorporated under the laws of the UAE (Registration No.: DMCC177608) having its registered office at Unit No: 205B, JBC1, Plot No: JLT-PH1-G2A, Jumeirah Lakes Towers, Dubai, UAE (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ROYALTY AND SUBLICENSE INCOME AGREEMENTRoyalty and Sublicense Income Agreement • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • Delaware
This ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”), dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”), (ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).
